miRNA-155 Modulates the Malignant Biological Characteristics of NK/T-Cell Lymphoma Cells by Targeting FOXO3a Gene

This study investigated the effects of miRNA-155 on malignant biological characteristics of NK/T-cell lymphoma cell lines and the possible mechanism. The expression of miRNA-155 was detected in lymphoma cell lines from different sources （SNK-6, YTS, Jurkat and DOHH2） by real-time PCR. Lentiviral vectors （pLL3.7） that could overexpress or downexpress miRNA-155 were constructed. Recombinant lentiviral particles were prepared and purified, and their titers determined. The expression of miRNA-155 in the infected SNK-6 cells and the cell proliferation were detected by PCR and CCK-8, respectively. Flow cytometry was used to determine the apoptosis of infected SNK-6 cells. The target of miRNA155 was predicted from Targetscan website. The effect of miRNA155 on FOXO3a expression was examined by Western blotting. The results showed that among the human NK/T-cell lymphoma cell lines SNK-6, YTS, Jurkat and DOHH2, the expression of miRNA-155 was highest in SNK-6. The infection efficiency of the recombinant lentivirns in SNK-6 was more than 70% at multiplicity of infection （MOI） of 100. The expression of miRNA-155 was significantly increased in SNK-6 cells infected by lentivirus vectors with high expression of miRNA-155 （4 times higher than the control group）, and profoundly decreased in those infected with lentivirnses with low expression of miRNA-155. The proliferation of letivirns-infected SNK-6 cells was decreased as the expression of miRNA-155 reduced. The apoptosis rate was increased with the reduction in the expression of miRNA-155. FOXO3a was found to be a possible target of miRNA155, as suggested by Targetscan website. Western blotting showed that the expression of FOXO3a was significantly elevated in SNK-6 cells with miRNA-155 inhibition. It was concluded that reduction in miRNA-155 expression can inhibit the proliferation of SNK-6 lymphoma cells and promote their apoptosis, which may be associated with regulation of FOXO3a gene.

Extranodal natural killer/T-cell lymphoma,nasal type:epidemiology study

Extranodal natural killer （NK）IT-cell lymphoma, nasal type （ENKTCL） is a rarely kind of non-Hodgkin lymphoma （NHL）. It is much more frequent in Asian and Latin American countries than other part of the world. It typically affects nasal cavity. In China, one of its endemically places, ENKTCL accounts for 74%-96% of nasal NHL. Patients with ENKTCL usually show a highly aggressive clinical course, and its etiology is unclear. However, it is already proved that ENKTCL is associated with Epstein-Barr virus （EBV） infection, regardless patients＇, ethnicity and areas. Some studies show that the risk will increase among several occupations, such as farmer, who are frequently exposure to pesticides and chemical solvent and risk can be cut down if taking some protective measures.

Outcomes of patients treated with SVILE vs.P-GemOx for extranodal natural killer/T-cell lymphoma,nasal type:a prospective,randomized controlled study

Objective:To compare the efficacy and safety of the novel SVILE regimen with the P-GemOx regimen in patients with newly diagnosed extranodal natural killer/T-cell lymphoma,nasal type(ND-ENKTL).Methods:From April 2015 to July 2018,103 patients with ND-ENKTL were randomly assigned to SVILE(experimental group)or P-GemOx(control group)chemotherapy followed by radiotherapy and consolidation chemotherapy.The primary endpoint was the overall response rate after 3 cycles of chemotherapy,and secondary study endpoints were complete response(CR),progression-free survival(PFS),and overall survival(OS).Safety was also evaluated.Results:There were no significant differences in baseline characteristics in the experimentalvs.control groups.In experimental and control groups,respectively,the overall response rates were 91.7%vs.97.0%for stageI/II and 75.0%vs.72.2%for stage III/IV.The CR rates were 83.4%vs.97.0%for stage I/II and 68.8%vs.61.1%for stage III/IV.None of those differences were significant.There was no significant difference in PFS and OS between groups and between patients in stage I/II and stage III/IV.The 3-year PFS and OS in stage I/II were 88.3%vs.93.3%and 88.8%vs.97.0%,respectively.The 3-year PFS and OS in stage III/IV were 46.2%vs.65.7%and 68.8%vs.72.2%,respectively.The common adverse events were hematological toxicity,hepatotoxicity,and coagulation abnormalities,which were found to be reversible with supportive therapy.Conclusions:The novel SVILE regimen has comparable effects to those of P-GemOx in patients with ND-ENKTL and is well tolerated.SVILE is a therapeutic option for ND-ENKTL.

Gastrosplenic fistula occurring in lymphoma patients: Systematic review with a new case of extranodal NK/T-cell lymphoma

AIM To provide the overall spectrum of gastrosplenic fistula(GSF) occurring in lymphomas through a systematic review including a patient at our hospital.METHODS A comprehensive literature search was performed in the MEDLINE database to identify studies of GSF occurring in lymphomas. A computerized search of our institutional database was also performed. In all cases, we analyzed the clinicopathologic/radiologic features, treatment and outcome of GSF occurring in lymphomas. RESULTS A literature search identified 25 relevant studies with 26 patients. Our institutional data search added 1 patient. Systematic review of the total 27 cases revealed that GSF occurred mainly in diffuse, large B-cell lymphoma(n = 23), but also in diffuse, histiocytic lymphoma(n = 1), Hodgkin's lymphoma(n = 2), and NK/T-cell lymphoma(n = 1, our patient). The common clinical presentations are constitutional symptoms(n = 20) and abdominal pain(n = 17), although acute gastrointestinal bleeding(n = 6) and infection symptoms due to splenic abscess(n = 3) are also noted. In all patients, computed tomography scanning was very helpful for diagnosing GSF and for evaluating the lymphoma extent. GSF could occur either post-chemotherapy(n = 10) or spontaneously(n = 17). Surgical resection has been the most common treatment. Once patients have recovered from the acute illness status after undergoing surgery, their long-term outcome has been favorable. CONCLUSION This systematic review provides an overview of GSF occurring in lymphomas, and will be helpful in making physicians aware of this rare disease entity.

Primary Testicular NK/T-Cell Lymphoma:A Study of Two Cases and Review of Literature

Primary testicular NK/T-cell lymphoma is an extremely rare entity progressed rapidly.The aim of this study was to examine clinical and pathological features of primary testicular NK/T-cell lymphoma and to investigate the effective diagnosis and prognosis.In this paper,the two cases of primary testicular NK/T-cell lymphoma were observed by light microscopy,immunohistochemistry and examined by in situ hybridization for Epstein-Barr Virus（EBV） DNA and the literatures were reviewed.The two patients respectively present with bilateral and right-side painless testicular enlargement.The morphology of neoplastic cells of case 1 were small to medium,tumor cells of case 2 were small,medium and large mixed.The tumor cells grew diffusely with irregular and distort nuclear,destructed the organizational structure of the normal testis,and damaged blood vessels,meanwhile,coagulation necrosis was exist.Immunohistochemical staining of neoplastic cells showed positive for CD45,CD2,CD56,CD3ε（cytoplasm staining pattern）,CD45RO and Granzyme B,and negative for CD57,CD20,CD79α,CD30,CK,MPO,TdT,Bcl-2 and PLAP were negative.In addition,the EBV DNA was detected in the lymphoma by In situ hybridization.In conclusion,the expression of CD56,CD3ε,and Granzyme B associated proteins and EBV examination by in situ hybridization play a vital role in diagnosis and differential diagnosis of primary testicular NK/T-cell lymphoma.

Lymphomatoidgastropathy mimicking extranodal NK/T cell lymphoma,nasal type:A case report

Extranodal natural killer(NK)/T-cell lymphoma,nasal type,exhibits aggressive tumor behavior and carries a poor prognosis.Recently,lymphomatoid gastropathy with NK/T cell infiltration into gastric mucosa has been recognized as a pseudo-malignant disease which regresses without treatment.Because the conventional immunohistochemical criteria of lymphomatoid gastropathy is similar to that of extranodal NK/T-cell lymphoma nasal type,it is difficult to distinguish between the two conditions by histopathological evaluation only.Here,we report a rare case of lymphomatoid gastropathy in a 57-year-old female.Gastroendoscopy on routine check-up revealed elevated reddish lesions < 1 cm in diameter in the gastric fornix and body.Although repeat endoscopies at 1 and 6 mo later revealed no gastric lesions at any locations without any treatments,at 12 mo later gastric lymphomatoid lesions recurred at gastric fornix and body.Histological examination of endoscopic biopsy specimens at 12 mo showed atypical NK cell infiltration with CD3+,CD4-,CD5-,CD7+,CD8-,CD20-,CD30-,CD56+,CD79a-and T-cell-restricted intracellular antigen-1+ into gastric mucosa.After treatment for Helicobacter pylori(H.pylori) eradication,the lesions disappeared in all locations of the gastric fornix and body over the subsequent 12 mo.Here,we report a case of H.pylori-positive lymphomatoid gastropathy with massive NK-cell proliferation,and also review the literature concerning newly identified lymphomatoid gastropathy based on comparison of extra nodal NK/T-cell lymphoma nasal type.In any case,these lesions are evaluated with biopsy specimens,the possibility of this benign entity should be considered,and excessive treatment should be carefully avoided.Close follow-up for this case of lymphomatoid gastropathy is necessary to exclude any underlying malignancy.

Three-dimensional conformal radiotherapy plus concurrent DICE chemotherapy for early-stage nasal-type natural killer/T-cell lymphoma of Waldeyer's ring: A single-institution study

Objective Nasal-type natural killer/T-cell lymphoma of Waldeyer＇s ring （WR-NK/TL） has different clinico- pathological characteristics from those of other subtypes of NK/T lymphoma; thus, the optimal treatment remains unclear. To find a more effective treatment model for WR-NK/TL, we conducted a single-center study of concurrent radiochemotherapy. Methods Forty-five patients with newly diagnosed stage IE to liE WR-NKTL were randomly divided into two groups. The 23 cases in the concurrent radiochemotherapy group were treated with three-dimensional conformal radiotherapy （48-52 Gy） and 2 courses of DICE （dexamethasone, ifosfamide, cisplatin, and etoposide） synchronous chemotherapy. The 22 cases in the radiotherapy group only received three-dimen- sional conformal radiotherapy （50-54 Gy）. The primary end points were overall survival （OS）, progression- free survival （PFS）, and toxicity. Results The 1-, 3-, and 4-year OS and PFS rates were 95.5%, 65.6%, and 45.9%, and 86.4%, 56.0%, and 46.7% in the radiotherapy group, and 100%, 88.5%, and 88.5%, and 100%, 82.0%, and 73.8% in the concurrent radiochemotherapy group, respectively. The OS （P = 0.0477） and PFS rates （P = 0.0488） were higher in the concurrent radiochemotherapy group than in the radiotherapy group. The overall re- sponse rate was 100% in both the radiotherapy group [complete response （CR）, 18 cases] and concurrent radiochemotherapy group （CR, 22 cases）. The concurrent radiochemotherapy group had more severe side effects, especially grade 3 ＋ 4 events, such as leukopenia, anorexia, and stomatitis. However, side effects benefiting from excellent oral care were endurable. Conclusion Radiotherapy plus concurrent DICE chemotherapy may be an effective and safe compre- hensive treatment for patients with WR-NKTL.

Intestinal T-cell lymphomas:A retrospective analysis of 68 cases in China

AIM: To investigate the clinical features, diagnosis, treatment and prognosis of intestinal T-cell lymphomas (ITCL) by retrospective analysis.

Primary site and regional lymph nodeinvolvement are independent prognosticfactors for early？stage extranodal nasal？typenatural killer/T cell lymphoma

Background:Nasal-type extranodal natural killer/T-cell lymphoma(ENKTCL) originates primarily in the nasal cavity or extra-nasal sites within the upper aerodigestive tract.However,it is unclear whether the primary site can serve as an independent prognostic factor or whether the varying clinical outcomes observed with different primary sites can be attributed merely to their propensities of regional lymph node involvement.The aim of this study was to investigate the prognostic implications of the primary site and regional lymph node involvement in patients with early-stage nasal-type ENKTCL.Methods:To develop a nomogram,we reviewed the clinical data of 215 consecutively diagnosed patients with early-stage nasal-type ENKTCL who were treated in Sun Yat-sen University Cancer Center with chemotherapy and radiotherapy between 2000 and 2011.The predictive accuracy and discriminative ability of the nomogram were determined using a concordance index(C-index) and calibration curve.Results:The 5-year overall survival(OS) and progression-free survival(PFS) rates of patients with nasal ENKTCL were higher than those of patients with extra-nasal ENKTCL(OS:68.2%vs.46.0%,P = 0.030;PFS:53.4%vs.26.6%,P = 0.010).The 5-year OS and PFS rates of patients with Ann Arbor stage IE ENKTCL were higher than those of patients with Ann Arbor stage HE ENKTCL(OS:66.3%vs.59.2%,P = 0.003;PFS:51.4%vs.40.3%,P = 0.009).Multivariate analysis showed that age >60 years,ECOG performance status score >2,elevated lactate dehydrogenase(LDH) level,extranasal primary site,and regional lymph node involvement were significantly associated with lower 5-year OS rate;age >60 years,elevated LDH level,extra-nasal primary site,and regional lymph node involvement were significantly associated with lower 5-year PFS rate.The nomogram included the primary site and regional lymph node involvement based on multivariate analysis.The calibration curve showed good agreement between the predicted and actual 5-year OS and PFS rates,and the C-indexes of the nomogram for the OS and PFS rates were 0.697 and 0.634,respectively.Conclusions:The primary site and regional lymph node involvement are independent prognostic factors for earlystage ENKTCL treated with chemotherapy followed by definitive radiotherapy.

107例鼻型NK/T细胞淋巴瘤临床特点和预后分析

目的分析107例鼻型NK／T细胞淋巴瘤的临床特点，探讨影响预后的因素。方法回顾性分析2002年1月-2010年12月间福建省肿瘤医院收治的107例完整资料的鼻型NK／T细胞淋巴瘤患者，将临床特点及实验室检查结果进行单因素分析，单因素分析有统计学意义的指标纳入多因素分析。结果107例患者男女比例为2．2：1（74：33），年龄9～83岁，中位年龄42岁。原发部位：鼻腔75例（70％）、韦氏环24例（22％）、其他部位8例；伴颈部淋巴结受侵12例（11％）、骨髓侵犯2例；82％为Ann Arbor分期Ⅰ／Ⅱ期；83％国际预后指数评分为0～1分，52％伴有B症状。单纯化疗26例、单纯放疗26例、化放疗综合治疗55例。初治完全缓解率61％，5年生存率47．2％，多因素分析显示年龄、分期、近期疗效是NK／T细胞淋巴瘤的独立预后因素。结论鼻型NK／T细胞淋巴瘤主要侵犯鼻腔和韦氏环，男性多见，常伴B症状，放化疗为其主要治疗手段，年龄、分期、近期疗效可作为预后参考因素。

CT和MRI对原发鼻腔鼻窦结外鼻型NK/T细胞淋巴瘤的临床诊断价值

目的原发鼻腔鼻窦结外鼻型NK/T细胞淋巴瘤(ENKTCL)早期诊断困难,有一定的误诊率。文中旨在分析和总结原发鼻腔鼻窦ENKTCL的CT和MRI表现,探讨CT和MRI对原发鼻腔鼻窦ENKTCL的临床诊断价值。方法回顾性分析2012年1月至2017年12月南京鼓楼医院耳鼻咽喉头颈外科13例原发鼻腔鼻窦ENKTCL的临床资料及影像学资料。分别行CT平扫、增强及MRI平扫、增强,分析CT表现和MRI表现。结果 13例患者CT平扫示鼻腔鼻窦内软组织密度影,肿瘤内密度尚均匀,骨窗可显示骨质破坏,主要表现为鼻腔中线及鼻窦区域软组织肿块伴骨质破坏,骨质破坏多表现为骨质浸润性吸收,病变软组织范围明显大于骨质破坏范围。10例患者CT增强后肿瘤呈轻至中度不均匀强化。10例患者MRI平扫肿瘤显示T1WI等信号,T2WI呈稍高信号,强化后呈轻度到中度不均匀强化。10例患者伴阻塞性鼻窦炎,T1WI呈低信号,T2WI呈高信号,增强后边缘强化。结论原发于鼻腔鼻窦ENKTCL的CT和MRI表现有一定的特征性,结合患者临床表现及体征,常规行CT和MRI检查能够较准确的描述病变的部位及侵犯范围,对于临床早期诊断及评估疾病预后有重要的临床意义。

62例鼻型NK/T细胞淋巴瘤的预后因素分析

背景与目的:鼻型NK/T细胞淋巴瘤是具有独特生物学特性的疾病类型,由于发病率相对较低,其确切的临床预后特征尚未完全阐明。本研究拟分析华南地区鼻型NK/T细胞淋巴瘤的临床特点及可能的预后因素,为进一步的研究提供参考。方法:回顾性分析中山大学肿瘤防治中心1999年1月至2004年12月间收治的鼻型NK/T细胞淋巴瘤患者的资料。详细的临床特点及实验室检查结果均纳入单因素分析,单因素分析中有统计学意义的指标纳入多因素分析。结果:62例鼻型NK/T细胞淋巴瘤患者纳入本研究,男女比例约为3∶1,患者中位年龄42岁。92%的患者为AnnArborⅠ/Ⅱ期,76%的患者属于IPI(internationalprognosticindex)低危组。治疗前ECOGPS(performancestatus)评分0～1的患者占总数的92%,贫血见于26%的患者,而53%的患者伴随有B症状。全组患者中位生存时间27个月(95%CI:10～45个月)。单因素分析显示,性别、年龄、PS评分、乳酸脱氢酶水平、IPI、B症状、Hb(hemoglobin)浓度及白细胞数等指标与预后相关。多因素分析显示,治疗前Hb<110g/L、有B症状及PS评分>1是鼻型NK/T细胞淋巴瘤患者的不良预后因素。治疗模式的选择对患者的预后亦产生显著影响。结论:Hb浓度、B症状及PS评分可以作为判断鼻型NK/T细胞淋巴瘤预后的参考因素。

鼻NK/T细胞淋巴瘤的免疫表型和细胞毒颗粒蛋白的表达及其意义

目的:观察鼻NK/T细胞淋巴瘤的免疫表型和细胞毒颗粒蛋白的表达及其意义。方法:采用DAKOEnVision两步法在44例鼻NK/T细胞淋巴瘤病例中检测CD3、CD20、CD43、CD45、CD45RO、CD56、CD57和CD79α等8种常用淋巴细胞表面标记物和3种细胞毒颗粒蛋白TIA-1、Granzyrme-B、perforin的表达,观察和分析检测结果,并与发生在相同部位的其他常见恶性淋巴瘤的检测结果进行比较分析。结果:44例鼻NK/T细胞淋巴瘤均表达CD45;CD3阳性率为43%,阳性定位在细胞质;CD56、CD43和CD45RO的阳性率分别为52%、45%和52%,CD20、CD79α和CD57均为阴性。TIA-1、Granzyrme-B和perforin的阳性率分别为100%、930%和95%,对照组的23例鼻腔和鼻咽T、B细胞淋巴瘤中均不表达。结论:鼻NK/T细胞淋巴瘤的免疫表型不一致,并非所有病例显示CD56阳性,石蜡切片中CD3的阳性定位与通常的外周T细胞淋巴瘤不同。细胞毒性颗粒蛋白在肿瘤细胞中的高表达,提示它们可能为NK细胞来源。细胞毒性颗粒蛋白是鼻NK/T细胞淋巴瘤诊断和鉴别诊断重要标志。

64例早期鼻腔NK/T细胞淋巴瘤的疗效和预后分析

目的:回顾性分析64例早期原发鼻腔NK/T细胞淋巴瘤患者的疗效,探讨其预后因素。方法:收集1993年6月至2005年10月间收治的64例早期原发鼻腔NK/T细胞淋巴瘤患者的资料。根据Ann Arbor分期标准,64例患者均为ⅠE/ⅡE期,单纯放疗23例,其余41例接受放、化联合治疗。单因素分析采用Kaplan-Meier法,多因素分析运用Cox比例风险模型。结果:全组中位生存时间41个月,5年总生存(OS)率为59.17%。单纯放疗组和联合放化疗组5年OS率分别是57.86%和61.45%(P=0.47),二者对生存率影响无明显统计学差异。多因素回归分析表明,治疗前PS评分≥2分、初诊时病灶超腔、首程治疗完全缓解率(CR)低是预后不良的独立因素。结论:对早期鼻腔NK/T细胞淋巴瘤的治疗,放疗加CHOP方案化疗对远期生存率没有提高。治疗前PS评分、初诊时病灶是否超腔、首程治疗完全缓解率,可作为判断鼻腔NK/T细胞淋巴瘤临床预后的参考指标。

鼻型NK/T细胞淋巴瘤研究进展

目的:总结鼻型NK/T细胞淋巴瘤的研究进展。方法:应用Medline及CNKI期刊全文数据库检索系统,检索1992-01-2007-12关于鼻型NK/T细胞淋巴瘤分子发病机制、临床病理和免疫组化研究及治疗方面的文献。最后纳入32篇。结果:鼻型NK/T细胞淋巴瘤主要发生于鼻腔及面中线部位,也可以发生于其他部位,如皮肤、胃肠道、中枢神经系统、肺以及睾丸等。病理学上,肿瘤细胞胞质CD3及CD56阳性,同时表达细胞毒性颗粒蛋白,如TIA-1等,往往也表达EBV病毒抗原。鼻型NK/T细胞淋巴瘤预后不良,易复发且对治疗不敏感。新的国际预后指数已用于评价该肿瘤的预后。从单独放疗到高剂量的化疗以及造血干细胞移植术等几种治疗手段已应用于临床。结论:鼻型NK/T细胞淋巴瘤与EB病毒有关,具有独特的临床病理特点,放化疗联合运用可提高其治疗效果。

鼻部NK/T细胞淋巴瘤累及皮肤

为了探讨鼻部NK/T细胞淋巴瘤累及皮肤的临床表现、病理、免疫表型及EB病毒相关性。通过临床表现及病程,分析原发及累及部位。通过UCHL-1,CD56,多克隆CD3,CD8,CD20,TIA-1,粒酶B(GrB)等对肿瘤细胞免疫表型进行研究,E-BV-EBER探针原位杂交检测肿瘤细胞阳性率分析其病因及发病。结果本例皮肤及鼻部取材组织病理表现为坏死及中等大小的异型性肿瘤细胞增生浸润,UCHL-1+,CD56+,CD3+,CD8-,CD20-,TIA-1+,granzymeB+,为NK/T细胞淋巴瘤表型。EBV瘤细胞阳性率达60%,进一步证实为鼻部NK/T细胞淋巴瘤,EBV相关性。支持鼻部NK/T细胞淋巴瘤是具有特殊免疫表型,与EB病毒有高度相关性的独立疾病,临床进展迅速,病程短,提示为高度侵袭性。

不同治疗方案对鼻、鼻型NK/T细胞淋巴瘤疗效分析

目的:探讨鼻、鼻型NK/T细胞淋巴瘤的临床特征、治疗方法和预后。方法:收集自2004年1月-2010年1月在我院住院治疗的29例鼻、鼻型NK/T细胞淋巴瘤患者临床资料,分析其临床特点、治疗方案及预后。结果:治疗分CHOP方案组及L-ASP组,总有效率分别为56.3%和75.9%(P=0.045)。两组5年OS率和DFS率分别为43.75%、61.54%(P=0.038)及18.8%、46.15%(P=0.009),具有统计学意义。难治组7例经VDLP方案补救化疗后总有效率为71.3%。B组症状、临床分期及KPS评分可能对患者的生存产生影响。结论:对于临床早期的鼻、鼻腔NK/T细胞淋巴瘤患者,初治时可以选择CHOP方案治疗,而中、晚期病例及CHOP方案治疗无效的病例,选择以左旋门冬酰胺酶为主的联合化疗结合放疗综合治疗可取得较好疗效。

自体造血干细胞移植治疗结外NK/T细胞淋巴瘤鼻型9例临床分析

目的观察放/化疗加APBSCT治疗NK/T细胞淋巴瘤鼻型的疗效。方法用CHOP＋Lasp方案1个疗程、CHOP（或MOED、COED）＋HD-MTX方案化疗2～3个疗程，行干细胞动员、采集，CEAC方案预处理及APBSCT及移植后局部病灶的放疗；病程中共行3次鞘内注射化疗药，6～8次联合化疗。结果Ⅰ～Ⅱ期患者移植后1年生存率55.6%（5/9例），2年生存率为44.4%（4/9例）；Ⅲ～Ⅳ期患者移植后3个月～1年内由CR到病情复发，死亡4例，2年生存率为0。结论NK/T细胞淋巴瘤鼻型分期晚的治疗效果差，大剂量化/放疗＋APBSCT治疗NK/TCL可能是有效的措施之一。

鼻NK/T细胞淋巴瘤1例

报道1例以皮肤为首发症状的鼻NK/T细胞淋巴瘤。患者男,48岁。双下肢、躯干、双上肢陆续出现红色斑丘疹、结节及溃疡4月余,鼻腔发现新生物1月余。皮肤及鼻部组织病理示中、小淋巴样细胞弥漫浸润;免疫组化染色:CD56(+),LCA(+),UCLH-1(+),L26(-),CD57(-);EBER(+)。

鼻腔NK/T细胞淋巴瘤临床病理特征及诊断分析

目的探讨鼻腔NK/T细胞淋巴瘤的临床、病理特征,诊断和误诊原因。方法复习62例鼻腔NK/T细胞淋巴瘤的临床资料,应用组织病理学、免疫组化和原位杂交技术分析其临床特点、诊断、病理特征和免疫表型。结果鼻腔NK/T细胞淋巴瘤以鼻塞、涕血和头痛为主要症状,表现为面部中线破坏性病变。病理改变为肿瘤性淋巴样细胞弥漫或散在分布于凝固性坏死和多种炎细胞混合浸润的背景上。所有病例表达T细胞标记,不表达B细胞标记;NK细胞标记阳性5例;EB病毒mRNA阳性56例(90%)。结论鼻腔NK/T细胞淋巴瘤临床表现不典型,易误诊误治。免疫组化检查是确诊的重要方法。患者以T细胞为主,大多有EBV感染。